Journal
VACCINE
Volume 27, Issue 5, Pages 757-764Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.11.029
Keywords
Platycodin D (PD); Platycodon grandiflorum; Adjuvant; Hepatitis B surface antigen (HBsAg); Cellular and humoral; Th1/Th2 immune responses
Categories
Funding
- National Natural Science Foundation of China [30871888]
- Zhejiang Provincial Natural Science Foundation of China [R3080027]
- Administration of Traditional Chinese Medicine of Zhejiang Province [A2006Z017]
Ask authors/readers for more resources
The ideal adjuvants for hepatitis B vaccines should be capable of eliciting both strong humoral and cellular immune responses, especially Th1 cell and cytotoxic Tlymphocyte (CTL) responses. However, Alum used as adjuvants in the hepatitis B vaccines Currently commercialized offers limitation in inducing cell-mediated response. Therefore, a less hemolytic saponin platycodin D (PD) from the root of Platycodon grandiflorum has been explored for its potential as an alternative adjuvant. In order to compare the adjuvant activity with Alum, antigen-specific cellular and humoral immune responses were evaluated following immunization with a formulation containing hepatitis B surface antigen (HBsAg) adjuvanted with PD and Alum in mice. The Con A-, LPS-, and HBsAg-induced splenocyte proliferation and the serum HBsAg-specific IgG, IgG1, IgG2a, and IgG2b antibody titers in the HBsAg-immunized mice were significantly enhanced by PD (P < 0.05, P < 0.01 or P < 0.001). PD also significantly promoted the production of Th1 (IL-2 and IFN-gamma) and Th2 (IL-10) cytokines and up-regulated the mRNA expression of Th1 cytokines (IL-2 and IFN-gamma) in splenocytes from the mice immunized with HBsAg (P<0.001). Besides, PD remarkably increased the killing activities of natural killer (NK) cells and CTLs from splenocytes in the HBsAg-immunized mice (P<0.001), which may have important implications for vaccination against hepatitis B virus. The results indicated that PD has strong potential to increase both Cellular and humoral immune responses and elicit a balanced Th1/Th2 response against HBsAg, and that PD may be the candidates as adjuvants for use in prophylactic and therapeutic hepatitis B vaccine. (C) 2008 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available